Pfizer bags a Langer platform, buys Bind assets with a $40M bid
In the end, Pfizer saw the most value in Bind Therapeutics’ platform technology. Already partnered on new products, Pfizer has come up with a winning bid of $40 million for the troubled biotech’s assets.
Pfizer grabbed “substantially all” of the Cambridge, MA-based biotech’s assets out of a Chapter 11 auction, according to a statement. And NanoCarrier came in with the runner up offer for the assets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.